BioSpace News Archive

Sensient Technologies Corporation will hold its conference call to discuss 2017 fourth quarter and year end results at 10:00 a.m. CST on Friday, February 9, 2018.

Verastem today announced that a poster highlighting the synergistic effects of duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma was presented at ASCO-SITC Clinical Immuno-Oncology Symposium being held January 25-27, 2018 in San Francisco.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.33 per share.

The US Patent and Trademark Office previously upheld the validity of the patents rejecting multiple challenges filed by Ariosa.

Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.

Concept will become a separate operating company within its Materials Analysis segment where it has strong synergies with the activities of Malvern Panalytical.

The warrants will have a per share exercise price of $0.50, are exercisable immediately and will expire five years from the date of issuance.

For the fiscal first quarter, Hill-Rom reported earnings of $1.31 per diluted share compared to $0.36 per diluted share in the prior-year period.

At the effective time of the retirement, Mr. Greisch will also step down from the board of directors of the company.

Astra has Glaxo and its COPD treatment Trelegy Ellipta squarely in its sights.